montelukast + placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Perennial Allergic Rhinitis
Conditions
Perennial Allergic Rhinitis
Trial Timeline
May 1, 2003 โ Jan 1, 2009
NCT ID
NCT00590772About montelukast + placebo
montelukast + placebo is a approved stage product being developed by Merck for Perennial Allergic Rhinitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00590772. Target conditions include Perennial Allergic Rhinitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00599534 | Phase 2 | Withdrawn |
| NCT00406094 | Approved | UNKNOWN |
| NCT00189462 | Approved | Completed |
| NCT00189475 | Approved | Completed |
| NCT00590772 | Approved | Completed |
| NCT01011452 | Approved | Completed |
Competing Products
20 competing products in Perennial Allergic Rhinitis